LONDON–(BUSINESS WIRE)– Despite the fact that China lags behind in terms of the overall level of genetic engineering drugs, the industry has accumulated rich R&D and industrialization experience as well as capital reserves. Thus, with a host of genetic engineering drug patents to become due, Chinese enterprises, such as Walvax, are committed to the industrialization research of monoclonal antibody, long-acting recombinant protein drugs and other generic drugs with high technical barriers. In April this year, Walvax announced to invest in Shanghai Fengmao to develop and produce genetic engineering generic drugs such as rituximab, bevacizumab, adalimumab, panitumumab, denosumab and long-acting EPO Continue reading →